Table 2.
Baseline characteristics of trial participants (N = 246).
| Intervention | Control | P-value | |
|---|---|---|---|
| Number of participants | 119 (48.4%) | 127 (51.6%) | 0.61 |
| Mean age of participants ± Std. deviation | 13.67 ± 2.43 | 13.98 ± 2.72 | 0.35 |
| Gender of participants | |||
| Male | 63 (52.9%) | 60 (47.2%) | 0.44 |
| Female | 56 (47.1%) | 67 (52.8%) | |
| ART Regimen at baseline | |||
| Zidovudine/Lamivudine/Nevirapine | 67 (56.3%) | 45 (35.4%) | – |
| Tenofovir/Lamivudine/Efavirenz | 32 (26.9%) | 43 (33.9%) | |
| Tenofovir/Lamivudine/Dolutegravir | 5 (4.2%) | 16 (12.6%) | |
| Abacavir/Lamivudine/Lopinavir/ritonavir | 2 (1.7%) | 8 (6.3%) | |
| Zidovudine/Lamivudine/Lopinavir/ritonavir | 2 (1.7%) | 7 (5.5%) | |
| Tenofovir/Lamivudine Lopinavir/ritonavir | 5 (4.2%) | 4 (3.1%) | |
| Abacavir/Lamivudine/Efavirenz | 5 (4.2%) | 3 (2.4%) | |
| Zidovudine/Lamivudine/Efavirenz | 1 (0.8%) | 1 (0.8%) | |
| Number of participants with undetectable viral load (≤20 copies/ml) | 26/119 (21.8%) | 54/127 (42.5%) | <0.001 |
| Mean CD4+ count ± Std. deviation | 665 ± 685 | 665 ± 437 | 0.99 |
| Number of participants with ≥95% adherence | 61/119 (51.3%) | 35/127 (27.6%) | <0.001 |
Abbreviations.
Zidovudine/Lamivudine/Lopinavir/ritonavir.
Tenofovir/Lamivudine Lopinavir/ritonavir ART Antiretroviral therapy.